These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23538216)

  • 1. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.
    Smerage JB; Budd GT; Doyle GV; Brown M; Paoletti C; Muniz M; Miller MC; Repollet MI; Chianese DA; Connelly MC; Terstappen LW; Hayes DF
    Mol Oncol; 2013 Jun; 7(3):680-92. PubMed ID: 23538216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.
    Paoletti C; Muñiz MC; Thomas DG; Griffith KA; Kidwell KM; Tokudome N; Brown ME; Aung K; Miller MC; Blossom DL; Schott AF; Henry NL; Rae JM; Connelly MC; Chianese DA; Hayes DF
    Clin Cancer Res; 2015 Jun; 21(11):2487-98. PubMed ID: 25381338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
    Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
    Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study.
    Paoletti C; Miao J; Dolce EM; Darga EP; Repollet MI; Doyle GV; Gralow JR; Hortobagyi GN; Smerage JB; Barlow WE; Hayes DF
    Clin Cancer Res; 2019 Oct; 25(20):6089-6097. PubMed ID: 31358544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
    Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
    J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
    Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
    Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019.
    Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF;
    Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
    Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
    Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.
    Dirix L; Buys A; Oeyen S; Peeters D; Liègeois V; Prové A; Rondas D; Vervoort L; Mariën V; Laere SV; Vermeulen P
    Breast Cancer Res Treat; 2022 Jun; 193(2):437-444. PubMed ID: 35397078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
    Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
    Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.
    Bidard FC; Fehm T; Ignatiadis M; Smerage JB; Alix-Panabières C; Janni W; Messina C; Paoletti C; Müller V; Hayes DF; Piccart M; Pierga JY
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):179-88. PubMed ID: 23129208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell count and thrombosis in metastatic breast cancer.
    Beinse G; Berger F; Cottu P; Dujaric ME; Kriegel I; Guilhaume MN; Diéras V; Cabel L; Pierga JY; Bidard FC
    J Thromb Haemost; 2017 Oct; 15(10):1981-1988. PubMed ID: 28779538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial.
    Helissey C; Berger F; Cottu P; Diéras V; Mignot L; Servois V; Bouleuc C; Asselain B; Pelissier S; Vaucher I; Pierga JY; Bidard FC
    Cancer Lett; 2015 May; 360(2):213-8. PubMed ID: 25700777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.